. | New York’s diversity and strengths are enabling groundbreaking life science innovation… Through strategic investment in biopharmaceutical, device and diagnostic research, development and manufacturing, New York fuels the creation of cutting-edge healthcare solutions. New York is growing its life science industry through a broad range of economic development programs and public-private partnerships, supported by the state’s award-winning research talent. New York is expanding the state’s ability to commercialize research and spurring the growth of a world-class life science research cluster. | New York’s diversity and strengths are enabling groundbreaking life science innovation through strategic investment in biopharmaceutical, device and diagnostic research, development and manufacturing, New York fuels the creation of cutting-edge healthcare solutions. New York is growing its life science industry through a broad range of economic development programs and public-private partnerships, supported by the state’s award-winning research talent. And through its $620 million Life Science Initiative, New York is expanding the state’s ability to commercialize research and spurring the growth of a world-class life science research cluster. The mission of Empire State Development (“ESD”) is to promote a vigorous, inclusive and growing state economy, encourage business investment and job creation, and support diverse, local economies across New York State through the efficient use of loans, grants, tax credits, real estate development, marketing, and other forms of assistance. To support our economic development mission, ESD: invests strategically in infrastructure, innovation, place-making and revitalization, tradable sectors, and workforce development, with a focus on sustainability and historically disadvantaged populations across the state; is transparent and responsive to the needs of diverse communities and businesses across the state, including through the active participation of the Regional Councils; supports the retention and growth of existing businesses, the resilience of communities, and the development of new businesses and industries; promotes equality of economic opportunities for minority- and women-owned businesses (“MWBEs”) and Service-Disabled Veteran-Owned Businesses (“SDVOBs”); assists in the development of underutilized property to spur community revitalization, housing, and commercial activity; provides early-stage support for new ventures, including the research and development and commercialization of new technologies; and strengthens New York State’s innovation-based economy through partnerships with our acclaimed universities, promoting entrepreneurialism through the development of incubators and next-generation manufacturing and technology hubs across the state. | Empire State Development (ESD) is the lead economic development agency for New York and offers site selection support and access to robust incentives, including the $3B excelsior tax credit program which is enhanced for green projects. ESD focuses on attracting strategic industries including energy storage, while also investing significantly into preparing industrial sites. ESD facilitates the $400m FAST NY shovel ready grant program as well as the $300m POWER UP initiative. Together, these programs seek to create shovel ready, power ready sites well suited to advanced manufacturing. To date, the FAST NY program has improved over 4,000 acres of industrial property. The strategic business team at ESD provides tailored service to companies seeking sites, incentives, workforce information, at local connections in New York.
Destination Medical Center, EDA
Destination Medical Center (DMC) is a unique 20-year economic development initiative. The $5.6 billion plan is the largest in Minnesota’s history. With the expansion of Mayo Clinic and DMC growth, Rochester is a global destination for health and wellness and so much more. Rochester, Minnesota is its own special place. It spawned the world-renowned Mayo Clinic, home to those leading the way in life science discoveries and health care innovations. It’s the place people go to get better. Where developers are building an epicenter fueled by economic boom and dramatic growth. Where entrepreneurs come to find their place and discover the next big thing. The Destination Medical Center (DMC) initiative puts you in the middle of it all. | The DMC Initiative serves as a public-private partnership, combining private development by Mayo Clinic and other developers, as well as public funding from the City of Rochester, Olmsted County, and the State of Minnesota to facilitate and support public infrastructure. DMC promotes the City of Rochester, and more broadly, the County, and the State as a world destination medical center, to assist the patients, caregivers, residents, employees, and visitors in fully experiencing Rochester as a premier destination medical center, while providing extended economic development and opportunities for the City, the region, and the State.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
CorDx
CorDx manufactures point-of-care and over-the-counter rapid diagnostic products across a variety of categories, including infectious disease, reproductive & sexual health, substance abuse, and other health and marker tests. With authorization for use in the US (FDA), Europe (CE Mark) and China (NMPA), CorDx tests are known for their comfort, speed and accuracy. The flagship three-in-one test for Flu A/B & COVID-19 features a more comfortable synthetic nasal swab and provides reliable results in just 10 minutes. Since 2006, CorDx has developed diagnostic products while establishing a solid supply chain foundation, allowing it to provide better quality, more affordable tests for distributors, healthcare providers and patients alike. CorDx is a CorDx Union company, a biotechnology organization that delivers medical device solutions to healthcare industries and over a billion users in more than 170 countries. CorDx Union provides full-cycle support from life’s conception to its completion. Outside of healthcare, CorDx Union propels innovations in energy, AI quality management, and other platforms. Each member plays an important role in the CorDx ecosystem, all anchored around a vertically integrated supply chain that ensures users have access to the products they need when they need them.
Cor.Sync
Cor.Sync is a solution for fast and accurate heart attack diagnosis at the hospital emergency care. Myocardial infarction, also known as heart attack, is one of the biggest causes of death around the world. But its diagnosis requires, along with electrocardiogram, a blood test to measure a biomarker, called troponin. Nowadays it takes from 1 to 5 hours to measure troponin at laboratories, and half of the deaths by infarction happens inside hospital, while the patient is waiting for these results. Cor.Sync is a point of care testing platform, with a desktop device and biosensors, capable of measuring troponin in just 8 minutes with the same accuracy and price as a laboratory test.
Coherence Biotech Co. Ltd.
Coherence Bio is a lab automation company developing tools to accelerate AI based drug discovery, through end-to-end automation of cell-based testing.
Cincinnati Children’s Innovation Ventures
Cincinnati Children’s is a nationally ranked pediatric health system and a recognized leader in both pediatric and adult research. With a legacy of impact spanning more than 90 years—from Albert Sabin’s oral polio vaccine to pioneering discoveries in lung surfactant proteins—we continue to advance science that improves lives. As one of the largest pediatric research institutions in the U.S., we secure $300 million in external research funding annually and play a central role in shaping the future of biomedical innovation. Innovation is embedded in our culture. One-third of our 19,000 employees are engaged in research and innovation across a broad spectrum of life sciences. From breakthrough therapeutic candidates and biotech platforms to diagnostics, medical devices, software, and research tools, our teams are building a pipeline of technologies with the potential for real-world impact. Explore our innovation portfolio and partnership opportunities at cincinnatichildrens.org/innovation-ventures.
Certest Biotec
Certest Biotec, established in Spain in 2002 as an innovative and technology-based company, has always based its growth on the research and development of new products, and the exploration for new market niches and opportunities. The key to understand its success is the way to understand its organization: highly specialized and customer oriented. Certest Pharma part of Certest Biotec, is dedicated to building a platform for the development of RNA vaccines and oligotherapeutics, with a special focus on seeking improved formulations to enhance delivery. In that sense, Certest Pharma is specialized in the development of raw materials, amongst which lipids and more specifically, ionizable lipids, are one of the leading products. Certest´s Pharma three main areas are: Delivery technology: Ionizable lipids are a key element in the production of lipid nanoparticles (LNPs), and as such, have been widely used for the systemic delivery of RNA therapeutics. After the screening of more than a thousand ionizable lipids with our semi-rational design we are able to offer outperforming and custom made ionizable lipids for the effective targeted delivery of RNA therapeutics. API platform: This platform will cover, thanks to over 20 years of experience in the field, all the necessary steps for the design, development, and evaluation of effective mRNA and oligotherapeutics molecules. Also, a proprietary UTR sequence and codon optimization software have been developed showing higher results in protein expression. Enzymes for the production of mRNA have also been developed. Therapeutic products: Bringing together both areas Certest was granted to develop a new booster for TB vaccine and therefore be able to show the full capabilities of the company.
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first and is committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, Castle’s innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions. Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Using its expertise in advanced technologies, such as genomics, spatialomics, data analytics and artificial intelligence, Castle digs deep into treatment pathways to develop personalized, clinically actionable tests that can improve, and potentially transform, the management of diseases and patient outcomes. | At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.